Greenleaf Trust Sells 869 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Greenleaf Trust decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,252 shares of the medical equipment provider’s stock after selling 869 shares during the period. Greenleaf Trust’s holdings in Intuitive Surgical were worth $8,519,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Baystate Wealth Management LLC boosted its stake in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares in the last quarter. Atticus Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 41 shares during the period. OFI Invest Asset Management bought a new position in shares of Intuitive Surgical in the 3rd quarter worth approximately $25,000. Headinvest LLC purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at approximately $28,000. Finally, Stone House Investment Management LLC boosted its position in shares of Intuitive Surgical by 100.0% during the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG stock traded down $6.29 during trading on Friday, reaching $366.34. 3,966,068 shares of the company were exchanged, compared to its average volume of 1,675,699. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company has a market cap of $129.85 billion, a P/E ratio of 73.65, a PEG ratio of 5.81 and a beta of 1.36. The stock’s 50 day moving average price is $387.27 and its 200 day moving average price is $342.60.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the prior year, the company earned $1.00 EPS. The firm’s revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Insider Buying and Selling

In other news, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $376.06, for a total value of $9,147,659.50. Following the sale, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Gary S. Guthart sold 24,325 shares of Intuitive Surgical stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the completion of the sale, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $9,373,093.80. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock worth $95,927,097 in the last ninety days. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Stifel Nicolaus increased their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Mizuho upped their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday. Piper Sandler raised their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday. Finally, Royal Bank of Canada lifted their price target on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $381.24.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.